Alere wins FDA approval for healthcare connectivity hub

Telehealth player Alere says its new cellular connectivity hub has received clearance from the US Food and Drug Administration (FDA) for over-the-counter use.

Branded Alere HomeLink, the hub is designed to connect patients with providers and can be used in conjunction with other Alere (Waltham, MA, USA) products, says the company.

The product has also been granted a type of certification (CE Mark) that allows it to be marketed in Europe as well as in the US.

Alere describes the offering as part of its series of connected device technologies, aimed at allowing patients to self-test at home, while delivering data to clinical systems that can be accessed by healthcare providers.

By providing a gateway to Alere’s Connected Health platform, the HomeLink hub allows users to take advantage of a range of integrated products and services for health management.

Alere says the hub is to be deployed in health management programs for patients managing chronic conditions, such as diabetes and hypertension, at home.

But it can also be used on an over-the-counter basis with glucose meters, blood-pressure monitors weight scales and pulse oximeters.

Using Bluetooth systems, the HomeLink can be connected to a number of monitoring devices, and it features a seven-inch touch-screen display allowing patients to submit responses to disease management questions along with test measurements.

The device uses cloud technology to connect medical devices in the field to clinical backend systems.

“Alere HomeLink is the latest and most advanced of our connected device technologies, and enhances the provider-patient relationship by empowering patients to manage their health more successfully in their homes and making critical health information easily available to their providers through our Alere CloudCare Platform,” said Kent Dicks, Alere Connect’s chief executive.

Alere added that by bringing connectivity to the traditional healthcare delivery approach it hoped to improve health outcomes and lower costs.